-
Drawing from experience, Thyrocare CEO A Velumani suggests hiring humble individuals for business success, a sentiment shared by Zoho's Sridhar Vembu regarding untapped rural talent.
-
The founder and CEO of the medical laboratory company had on Saturday shared that his frugality has shocked his peers after an event at a 5-star hotel recently.
-
Thyrocare reported 23% YoY rise in revenue in December quarter
-
The founder group cumulatively holds under 2 percent in API Holdings. Each of the five co-founders held between 0.20 percent to 0.30 percent stake in the company, data showed.
-
Revenue came in at Rs 134.7 crore, up 5.2 percent from the year-ago quarter
-
Throcare had normalised EBITDA of 30 percent in Q2 of FY24 and in the same period the previous year.
-
The company reported a profit of Rs 15.43 crore in the same period last year.
-
Indian markets logged a third straight day of losses amid renewed Covid fears and RBI minutes that indicated that Governor Shaktikanta Das is not in favour of a pause in rate hikes just yet. Will the selloff continue as we step into the new year? Hemang Jani of Motilal Oswal Financial Services shares his outlook on the market going forward. Also catch NeoTrader’s Raja Venkatraman share his thoughts on stocks like RIL, Thyrocare and RailTel.
-
Diagnostics stocks saw a smart surge amid renewed fears of Covid outbreaks globally. Shares of Dr Lal PathLabs, Metropolis Healthcare, Vijaya Diagnostic Centre and Thyrocare rallied up to 6% in yesterday as investors see brighter prospects for diagnostics and healthcare businesses amid Covid scare. Catch Santosh Nair's thoughts on whether this rally will sustain and also catch his views on Sula Vineyards which makes its debut on the stock exchanges today and Lupin.
-
We expect an earnings CAGR in mid-teens in the medium term for VDC on the back of an expansion-led volume growth in the hinterland
-
European markets were lower on Monday after US Fed Chair Jerome Powell signalled higher interest rates would likely persist in a bid to tame soaring inflation. All sectors and major bourses slipped into negative territory. Tech stocks led the losses, down over 2%. Stocks in the spotlight today – Thyrocare, Orient Cement and BLS International. On the show today we try to decode whether the current market mood is a minor hiccup in the bull run or a deeper correction awaits?
-
Realising that the idea may take many by surprise, Thyrocare founder Dr Arokiaswamy Velumani revealed that goat farming was his first failure in life and he was only 10.
-
Thyrocare says the new tagline “Tests you can trust” reflects the transformation of the company over the last 25 years
-
One question that Thyrocare founder Dr A Velumani strikingly remembers compared him to Elizabeth Holmes, the fallen US biotech star, who was convicted on of defrauding investors in her blood-testing start-up Theranos.
-
Inorganic growth in this sector has been the norm across the globe, and most countries in the developed world have 5-6 large players dominating the space
-
Nearly 20 senior employees bought shares worth $5 million as part of the secondary sale while early investors sold their stakes in the firm and IIFL’s tech fund has picked up some stake, the report said.
-
Going forward, technology will be the differentiator, and Vijay Diagnostic's differentiated hub- and-spoke model calls for attention
-
Sourav Mallik, who has over 25 years of experience in investment banking and has advised on marquee transactions like Tech Mahindra’s acquisition of Satyam, believes that the Zomato market debut has confirmed that investors have the maturity to understand and appreciate new age companies. His top sectoral picks for deal activity include the digital ecosystem, healthcare, consumer, specialty chemicals and financial services
-
Dr A Velumani and his family will sell their 66.1 percent stake in Thyrocare to PharmEasy for Rs 4,546 crore. It’s a bumper value-unlocking for the family in the best year possible for the diagnostics business during the pandemic. The need for a change and de-risking are some of the key reasons for the sale, said Dr Velumani.
-
Siddharth Shah, CEO, API Holdings said that once the acquisition of Thyrocare is complete, Pharmeasy will aim to have its IPO within 6 to 18 months.
-
Docon Technologies Pvt Ltd, a 100 percent subsidiary of PharmEasy's parent firm API, will be the acquirer and shall make an open offer for an additional 26 percent stake.
-
Online medical store PharmEasy is in advanced talks to acquire diagnostics services chain Thyrocare in a deal worth about Rs 7,000 crore, people with direct knowledge of the development told Moneycontrol. Nisha Poddar shares the details. Watch:
-
The deal is likely to be announced soon given the IPO timelines of PharmEasy’s parent, API Holdings, people with direct knowledge of the development said.
-
Larger players from the diagnostic sector are positioned to gain more than the smaller ones and fragmented market share is an opportunity for them to expand their share.
-
Vaccine rollout will throw up opportunities not just for the domestic pharmaceutical and healthcare industry but also the logistics value chain, right from vaccine production, delivery, storage and then the actual immunisation
